CYCC - Cyclacel Pharmaceuticals Inc.

CYCC Stock Chart

CYCC Profile

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company headquartered in Berkeley Heights, New Jersey, focuses on advancing innovative therapies for cancer and other proliferative diseases. The company's robust pipeline includes fadraciclib, a promising cyclin dependent kinase inhibitor (CDK) currently undergoing Phase 1/2 clinical trials for solid tumors. Additionally, fadraciclib is being studied in combination with venetoclax for relapsed or refractory chronic lymphocytic leukemia, showcasing its potential across multiple indications.

Another key program in Cyclacel's portfolio is CYC140, a polo-like kinase inhibitor in Phase 1/2 clinical trials targeting advanced leukemias and solid tumors. The company's development efforts also encompass Sapacitabine, an orally available prodrug of CNDAC, a nucleoside analog undergoing Phase 1/2 clinical trials for acute myeloid leukemia and myelodysplastic syndrome. Moreover, Cyclacel is advancing seliciclib, a CDK inhibitor, through Phase 2 investigator-sponsored trials for conditions like Cushing's disease and advanced rheumatoid arthritis.

In pursuit of further clinical validation, Cyclacel Pharmaceuticals has established a significant clinical collaboration with the University of Texas MD Anderson Cancer Center. This collaboration aims to assess the safety and efficacy of three of Cyclacel's medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Through these strategic partnerships and a commitment to pioneering research, Cyclacel Pharmaceuticals continues to advance therapies that hold promise for improving outcomes in oncology and beyond.

CYCC Revenue Chart

CYCC Earnings